Andrew Krentz is an academic clinician and researcher focused on metabolic, endocrine and cardiovascular disorders.
His current positions include: Visiting Professor, Institute of Cardiovascular & Metabolic Research, University of Reading, UK; Academic Fellow, Centre for the Advancement of Sustainable Medical Innovation (CASMI), UK; Senior Research Fellow, ProSciento, San Diego, USA; Editor-in-Chief Cardiovascular Endocrinology & Metabolism, London, UK; Consultant Physician, London Diabetes Clinic, UK; Clinical Instructor, University of California San Diego, USA.
He is a National Council Member of the Royal Society of Medicine Section of Lipids, Metabolism & Vascular Risk, UK and an Elected Member of the Medical Scientific & Research Committee of the cholesterol charity, Heart UK. He is accredited as a clinical specialist by the European Society for Hypertension. In 2019, Andrew was awarded honorary Fellowship of the Faculty of Pharmaceutical Medicine in recognition of outstanding contributions to pharmaceutical medicine.
Andrew’s textbook publications include: Insulin Resistance: A Clinical Handbook (2002); The Metabolic Syndrome & Cardiovascular Disease (2007); Drug Treatment of Type 2 Diabetes (2012); Translational Research Methods for Diabetes, Obesity & Cardiometabolic Drug Development: A Focus on Early Phase Clinical Studies (2015).